Advertisement

Topics

Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics

2015-02-19 22:26:40 | BioPortfolio

Published on BioPortfolio: 2015-02-19T22:26:40-0500

Clinical Trials [764 Associated Clinical Trials listed on BioPortfolio]

Impact of Genetic Polymorphism on Drug-Drug Interactions Involving CYP2D6

CYP2D6 is characterized by a huge variability in the general population, mainly because of genetic polymorphism and drug-drug interactions (DDIs). CYP2D6 genotype is known to have an impac...

Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)

The purpose is to determine the hypercoagulable phenotype by thrombinography associated to an increased risk of symptomatic and objectively confirmed first venous thrombotic event. This is...

Intense Airway Eosinophilia in Asthma

In asthma, the type and importance of the inflammatory response in the airways has allows identification of different phenotypes. Of these, one of the most common is eosinophilic asthma, b...

LC-NMR Study Biomarkers to Detect Lung Cancer

Lung cancer is the most common cancer in men and the fourth most common cancer in women worldwide. Until today no effective method permits the early detection of lung cancer. Consequently,...

Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy

The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications.

PubMed Articles [13621 Associated PubMed Articles listed on BioPortfolio]

Delivery of amitriptyline by intravenous and intraperitoneal administration compared in the same animal by whole-body mass spectrometry imaging of a stable isotope labelled drug substance in mice.

The distribution and metabolism of a drug in the organism is dependent on the administration route as well as on the drug formulation. It is important to be able to assess which impact the administrat...

H NMR based pharmacometabolomics analysis of metabolic phenotype on predicting metabolism characteristics of losartan in healthy volunteers.

Inter-individual variability in drug metabolism and disposition is common in both preclinical and clinical researches. Losartan and its active metabolite EXP3174 present a high degree of inter-individ...

Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism.

For certain psychotropic drugs, such as clozapine or olanzapine, the influence of smoking on drug metabolism is well studied. Tobacco smoke increases the metabolism of drugs that are substrates for cy...

Computational Methods and Tools to Predict Cytochrome P450 Metabolism for Drug Discovery.

In this review we present important, recent developments in the computational prediction of cytochrome P450 (CYP) metabolism in the context of drug discovery. We discuss in silico models for the vario...

Intrauterine growth restriction may reduce hepatic drug metabolism in the early neonatal period.

The effects of intrauterine growth restriction (IUGR) extend well into postnatal life. IUGR is associated with an increased risk of adverse health outcomes, which often leads to greater medication usa...

Medical and Biotech [MESH] Definitions

The action of a drug that may affect the activity, metabolism, or toxicity of another drug.

Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.

Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.

The properties and processes of drug metabolism and drug interactions.

Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.

More From BioPortfolio on "Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial